

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/996,657
				Filing Date	November 29, 2001
				First Named Inventor	Charles Raymond Degenhardt
				Group Art Unit	1625
				Examiner Name	Rita J. Desai
Sheet	1	of	1	Attorney Docket Number	010785-9003-02

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
RD		BATES et al., "New ABC transporters in multi-drug resistance," Emerging Therapeutic Targets (2000) 4(5): 561-580
P		BATES et al., "A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma," Clinical Cancer Research (2004) 10:4724-4733
P		CHIBA et al., "Inhibitors of ABC-type drug efflux pumps: an overview of the current patent situation," Expert Opinion (2004) 14(4):499-508
P		DE MILITO et al., "Proton pump inhibitors may reduce tumour resistance," Expert Opinion Pharmacother. (2005) 6(7): 1049-1054
P		PUSZTAI, L. et al., "Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistance, advanced breast carcinoma," Amer. Cancer Soc. (2005) 682-691
RD		THOMAS, H. et al., "Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein," Cancer Control (2003) 10(2):159-165

Examiner Signature	<i>RJ Desai</i>	Date Considered	12/15/05
--------------------	-----------------	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.